Blood Test Study for Circulating Cells in Several Metastatic Cancers
Tests blood samples for special circulating cells in adults with spreading cancers.
Key facts
- Who runs it
- Institut Claudius Regaud
- Where
- Toulouse, FranceSee the site
- Trial code
- Registry title
- Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- Status
- Recruiting
- People taking part
- 450 people, planned
- Started
- 23 Jul 2025
- Expected to end
- 23 Jul 2029
- Type of study
- Interventional
- Treatments tested
- For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic cancer of certain types who have not yet started treatment for it. A blood sample is taken once.
- Age
- 18 years or older
- Sex
- Women and men
- Disease stage
- Metastatic disease (cancer that has spread). One of these types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervical carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous or nonseminomatous germ cell tumor.
- Earlier treatment
- Treatment for the metastatic disease (whatever the line) must not have started yet.
Main reasons for not taking part
- Localized disease (not spread)
- Pregnant or breast-feeding women
- A psychological, family, geographical or social situation that prevents following the study procedures
- Not affiliated to a French Social Security scheme
- Under legal protection or deprived of freedom by an administrative or legal decision
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 1. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
- 2. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
- 3. Age ≥ 18 years
- 4. Patient affiliated to a French Social Security scheme
- 5. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study
Who cannot take part
- 1. Patient with localized disease
- 3. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol
- 2. Pregnant or breast-feeding women
- 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Where in France
- Oncopole Claudius Regaud, IUCT-OToulouse, FranceContact: Thibaud VALENTIN, MDTaking people
About the trial
What the trial wants to find out
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.
Read full original descriptionShow less
Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.
450 patients will be enrolled in total.
The group in the trial
- Patients with metastatic cancerOther group
* Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients: * Cohort 1 : urothelial carcinoma * Cohort 2 : renal carcinoma * Cohort 3 : prostate adenocarcinoma * Cohort 4 : upper aerodigestive tract carcinoma * Cohort 5 : cervical carcinoma * Cohort 6 : adenocarcinoma of endometrium * Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients: * Cohort 7 : cutaneous melanoma * Cohort 8 : soft tissue sarcoma * Cohort 9 : seminomatous and nonseminomatous germ cell tumors
Treatment: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- Plain-language title
- Blood Test Study for Circulating Cells in Several Metastatic CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 June 2026